Home Drug IndexClinical Monograph

Pantoprazole Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Proton Pump Inhibitor (PPI)

Subclass

Benzimidazole Derivative

Speciality

Gastroenterology

Schedule (India)

Schedule H

Routes

Oral, Intravenous (IV)

Formulations

Tablets (Enteric-coated): 20 mg, 40 mg
Tablets (Gastro-resistant): 20 mg, 40 mg
Injection (Lyophilised powder for reconstitution): 40 mg/vial
Oral suspension: NOT AVAILABLE in India as monotherapy

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Gastroesophageal Reflux Disease (GERD)

Parameter	Dose
Starting dose	40 mg orally once daily (30–60 minutes before breakfast)
Titration	Not typically required; if inadequate response after 4 weeks, evaluate for complications or alternative diagnosis
Usual maintenance dose	20–40 mg once daily
Maximum dose	40 mg twice daily (specialist discretion for refractory cases)

Duration:

Symptomatic GERD: 4 weeks initially; reassess
Erosive GERD: 4–8 weeks
Maintenance therapy: Consider step-down to 20 mg or on-demand use after healing

Clinical Notes:

Administer before meals for optimal efficacy (requires acidic environment for activation)
Reassess diagnosis if no response after 8 weeks of adequate therapy
Consider endoscopy in non-responders or those with alarm features

2. Peptic Ulcer Disease (Gastric and Duodenal Ulcers)

Duodenal Ulcer:

Parameter	Dose
Starting dose	40 mg orally once daily
Titration	Not applicable
Usual maintenance dose	40 mg once daily
Maximum dose	40 mg once daily

Duration: 4 weeks (may extend to 8 weeks if not healed)

Gastric Ulcer:

Parameter	Dose
Starting dose	40 mg orally once daily
Titration	Not applicable
Usual maintenance dose	40 mg once daily
Maximum dose	40 mg once daily

Duration: 4–8 weeks

Clinical Notes:

Rule out malignancy in gastric ulcers (biopsy recommended)
Repeat endoscopy to confirm healing in gastric ulcers

3. Helicobacter pylori Eradication (as part of combination therapy)

Parameter	Dose
Starting dose	40 mg orally twice daily
Titration	Not applicable
Usual maintenance dose	40 mg twice daily
Maximum dose	40 mg twice daily

Standard Triple Therapy Regimen (14 days):

Pantoprazole 40 mg twice daily + Amoxicillin 1 g twice daily + Clarithromycin 500 mg twice daily

Alternative (Bismuth Quadruple Therapy — 14 days):

Pantoprazole 40 mg twice daily + Bismuth subsalicylate + Metronidazole + Tetracycline

Clinical Notes:

14-day regimens preferred over 7-day for higher eradication rates
Consider local clarithromycin resistance patterns
Confirm eradication with urea breath test or stool antigen (≥4 weeks after completing therapy and ≥2 weeks after stopping PPI)

4. Erosive Esophagitis

Parameter	Dose
Starting dose	40 mg orally once daily
Titration	Not applicable
Usual maintenance dose	40 mg once daily (healing); 20–40 mg once daily (maintenance)
Maximum dose	40 mg twice daily (severe cases)

Duration:

Healing: 8 weeks
Maintenance: Long-term in patients with high relapse risk (severe esophagitis, Barrett's oesophagus)

5. Zollinger-Ellison Syndrome and Pathological Hypersecretory Conditions

Parameter	Dose
Starting dose	40 mg orally twice daily
Titration	Increase based on gastric acid output measurements; titrate to maintain basal acid output <10 mEq/hour
Usual maintenance dose	80–160 mg/day in 1–2 divided doses
Maximum dose	240 mg/day (in divided doses; specialist supervision required)

Clinical Notes:

Individualise dose based on acid output measurements
May require long-term continuous therapy
Monitor serum gastrin levels periodically

6. Stress Ulcer Prophylaxis in Critically Ill Patients (Intravenous — Hospital/ICU Setting Only)

Parameter	Dose
Starting dose	40 mg IV once daily
Titration	Not applicable
Usual maintenance dose	40 mg IV once daily
Maximum dose	40 mg IV twice daily (bleeding prophylaxis in very high-risk patients)

Indications for Stress Ulcer Prophylaxis:

Mechanical ventilation >48 hours
Coagulopathy (platelets <50,000 or INR >1.5)
History of GI bleeding within past year
Traumatic brain injury, spinal cord injury, burns >35% BSA
Two or more minor risk factors (sepsis, ICU stay >1 week, occult GI bleed, high-dose corticosteroids)

Administration:

Reconstitute with 10 mL normal saline or 5% dextrose
Administer as IV bolus over 2–15 minutes OR as infusion over 15–30 minutes
Transition to oral therapy as soon as enteral feeding established

Clinical Notes:

Discontinue prophylaxis once patient is transferred out of ICU and tolerating enteral nutrition
Avoid routine use outside approved indications (de-escalation protocols important)

Secondary Indications – Adults (Off-label)

Indication	Dose	Duration	Supervision	Evidence Basis
NSAID-induced Ulcer Prophylaxis (OFF-LABEL)	20–40 mg orally once daily	As long as NSAID therapy continues	Not required	API Textbook; AIIMS protocols; Indian rheumatology practice
Functional Dyspepsia (Non-ulcer Dyspepsia) (OFF-LABEL)	20–40 mg orally once daily	Trial for 4–8 weeks; discontinue if no benefit	Not required	Limited efficacy; consider empirical trial; Indian GI practice
Prevention of Aspiration Pneumonitis (Pre-operative) (OFF-LABEL)	40 mg orally the night before and morning of surgery	Single pre-operative use	Anaesthesia supervision	Anaesthesia protocols; reduces gastric acidity and volume
Laryngopharyngeal Reflux (LPR) (OFF-LABEL)	40 mg orally twice daily	8–12 weeks; reassess	ENT/GI specialist recommended	Limited evidence; trial may be warranted in suspected LPR

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

⚠️ Not recommended in children below 5 years of age except under specialist supervision. Limited paediatric data available.

Primary Indications: GERD, Erosive Esophagitis

Oral Dosing (Children ≥5 years):

Weight	Dose	Frequency	Duration
15–40 kg	20 mg once daily	Once daily (before breakfast)	8 weeks
>40 kg	40 mg once daily	Once daily (before breakfast)	8 weeks

Parameter	Dose
Starting dose	Weight-based as above
Titration	Not typically required
Usual maintenance dose	20–40 mg once daily based on weight
Maximum dose	40 mg once daily

Intravenous Dosing (Hospital Setting — Limited Data):

0.8–1.6 mg/kg/day (maximum 40 mg/day)
Specialist supervision required

Safety Monitoring:

Monitor for symptoms of hypomagnesaemia with prolonged use
Assess nutritional status (vitamin B12, calcium, magnesium) if therapy >8 weeks
Evaluate for continued need periodically

Clinical Notes:

Tablets should be swallowed whole; do not crush or chew (enteric-coated)
If child cannot swallow tablets, consider omeprazole suspension or granules (better paediatric formulation availability)

Secondary Indications – Paediatrics (Off-label)

Indication	Age	Dose	Duration	Supervision	Evidence Basis
Stress Ulcer Prophylaxis in PICU (OFF-LABEL)	≥1 year	0.5–1 mg/kg IV once daily (maximum 40 mg)	Duration of ICU risk factors	Specialist only (PICU)	Extrapolated from adult data; IAP protocols
Zollinger-Ellison Syndrome (OFF-LABEL)	≥5 years	Individualised dosing based on acid output; starting 0.5–1 mg/kg twice daily	Long-term	Specialist only (Paediatric GI)	Case reports; extrapolated from adult data

Age Restrictions:

Not recommended below 5 years of age for routine use
Use in children 1–5 years only under paediatric gastroenterology supervision
Not recommended below 1 year of age

Renal Adjustments

No dose adjustment required in renal impairment (any severity).

Renal Function	Recommendation
Mild to Severe Impairment	No dose adjustment required
Haemodialysis	No supplemental dose required; not significantly dialysed
Peritoneal Dialysis	No dose adjustment required

Note: Pantoprazole is primarily hepatically metabolised; renal excretion of unchanged drug is minimal.

Hepatic adjustment

Contraindications

Known hypersensitivity to pantoprazole, substituted benzimidazoles, or any excipients
Co-administration with rilpivirine (reduced rilpivirine absorption leading to virological failure and resistance)
Co-administration with atazanavir (substantially reduced atazanavir absorption)

Cautions

Long-term use (>8–12 weeks): Risk of vitamin B12 deficiency, hypomagnesaemia, increased fracture risk (hip, wrist, spine), Clostridioides difficile-associated diarrhoea
Gastric malignancy: Rule out before initiating therapy; PPIs may mask symptoms of gastric cancer — investigate non-responders or those with alarm features (weight loss, dysphagia, GI bleeding, anaemia)
Concurrent diuretics or digoxin: Monitor electrolytes (particularly magnesium and potassium)
Chronic kidney disease: Although no dose adjustment needed, be aware of potential acute interstitial nephritis and chronic kidney disease progression with long-term PPI use
Osteoporosis risk factors: Use lowest effective dose for shortest duration; ensure adequate calcium and vitamin D intake
Lupus erythematosus: Rare reports of subacute cutaneous lupus erythematosus (SCLE) and systemic lupus exacerbation
Fundic gland polyps: Increased risk with long-term use (>1 year); usually benign and reversible

Pregnancy

Parameter	Information
Overall Safety	Limited human data; animal studies show no teratogenicity; generally considered acceptable when indicated
Risk	No confirmed teratogenic risk in humans; considered safer than untreated severe GERD
Preferred Alternatives	Omeprazole (most human pregnancy data available among PPIs); antacids or H2 blockers for mild symptoms
When Use May Be Justified	Moderate to severe GERD unresponsive to lifestyle modifications and antacids; erosive esophagitis; use at lowest effective dose for shortest duration
Monitoring	Maternal symptom control; no specific fetal monitoring required

Lactation

Parameter	Information
Compatibility	Likely compatible; very low levels expected in breast milk based on pharmacokinetic properties
Expected Drug Level in Milk	Very low (pantoprazole is highly protein-bound and acid-labile)
Preferred Alternatives	Omeprazole (more breastfeeding data available); famotidine (H2 blocker)
Infant Monitoring	Monitor for GI disturbances (diarrhoea, constipation), feeding difficulties, weight gain (rare concerns)
Recommendation	Generally acceptable for short-term use during breastfeeding

Elderly

Parameter	Recommendation
Starting dose	20–40 mg once daily (same as adults; consider starting at 20 mg)
Titration	Not typically required; use lowest effective dose
Maximum recommended	40 mg once daily for most indications; avoid high doses unless clearly indicated
Increased Risks	Increased fracture risk (hip, spine, wrist); hypomagnesaemia (especially with concurrent diuretics); vitamin B12 deficiency with long-term use; Clostridioides difficile infection; pneumonia (community-acquired)
Additional Precautions	Review indication periodically; de-escalate or discontinue when possible; ensure adequate calcium, vitamin D, and B12 intake; monitor magnesium levels if on long-term therapy or diuretics

Major drug interactions

Interacting Drug	Mechanism	Effect	Management
Rilpivirine	Reduced gastric acidity decreases rilpivirine absorption	Significant reduction in rilpivirine levels; risk of HIV treatment failure and resistance	Contraindicated — avoid combination
Atazanavir	Reduced gastric acidity decreases atazanavir absorption	Significantly reduced atazanavir levels; risk of HIV treatment failure	Contraindicated — avoid combination; if unavoidable, use atazanavir/ritonavir 400/100 mg with food, PPI ≤20 mg, and administer simultaneously
Methotrexate (high-dose)	Possible inhibition of renal tubular secretion of methotrexate	Increased methotrexate levels and toxicity risk	Consider temporary PPI discontinuation during high-dose methotrexate therapy; monitor methotrexate levels
Clopidogrel	CYP2C19 inhibition (minimal with pantoprazole)	Potential reduction in active clopidogrel metabolite (less significant than with omeprazole/esomeprazole)	Pantoprazole preferred PPI if PPI required with clopidogrel; cardiology input if recent ACS/PCI

Moderate drug interactions

Interacting Drug	Effect	Management
Warfarin	Variable reports of increased INR	Monitor INR when initiating or discontinuing pantoprazole; adjust warfarin dose as needed
Digoxin	Increased digoxin absorption due to elevated gastric pH	Monitor digoxin levels, especially in elderly or those with renal impairment; risk higher if hypomagnesaemia present
Iron supplements (ferrous salts)	Reduced iron absorption due to elevated gastric pH	Take iron supplement with food or vitamin C; consider parenteral iron if deficiency persists
Ketoconazole, Itraconazole, Posaconazole	Reduced antifungal absorption (requires acidic environment)	Separate dosing; use antifungals that do not require acidic pH (fluconazole, voriconazole); or administer with acidic beverage
Vitamin B12	Reduced absorption with long-term PPI use	Monitor B12 levels annually in long-term users; supplement if deficient
Mycophenolate mofetil	Reduced absorption of mycophenolic acid (enteric-coated formulation)	Monitor mycophenolate levels and clinical efficacy; consider mycophenolate sodium if clinically appropriate
Bisphosphonates (oral)	No direct interaction but additive bone risk	Ensure adequate calcium and vitamin D; monitor bone health in long-term concurrent use
Tacrolimus	Possible increased tacrolimus levels	Monitor tacrolimus trough levels when initiating or discontinuing PPI

Common Adverse effects

Headache
Diarrhoea
Nausea
Abdominal pain, flatulence
Dizziness
Arthralgia
Constipation
Dry mouth
Rash (mild)

Serious Adverse effects

Adverse Effect	Clinical Action
Clostridioides difficile-associated diarrhoea (CDAD)	Discontinue PPI; test for C. difficile toxin; treat as per guidelines; consider alternative acid suppression if essential
Hypomagnesaemia (may cause tetany, arrhythmias, seizures)	Check magnesium levels; discontinue PPI; supplement magnesium; may recur on rechallenge
Acute Interstitial Nephritis	Discontinue immediately; nephrology referral; usually reversible but may progress to chronic kidney disease
Vitamin B12 Deficiency (with long-term use)	Monitor annually in long-term users; supplement if deficient
Bone Fractures (hip, spine, wrist — with long-term high-dose use)	Use lowest effective dose; ensure calcium and vitamin D adequacy; bone density monitoring in high-risk patients
Subacute Cutaneous Lupus Erythematosus (SCLE) (rare)	Discontinue PPI; dermatology referral; rash usually resolves after discontinuation
Fundic Gland Polyps (benign; with long-term use)	Usually benign; endoscopic surveillance as per GI practice; often regress after PPI discontinuation
Anaphylaxis / Angioedema (rare)	Discontinue permanently; emergency management
Severe Skin Reactions (SJS/TEN) (very rare)	Discontinue immediately; hospitalisation; dermatology consultation

Monitoring requirements

Timing	Parameters
Baseline	Evaluate for alarm symptoms (dysphagia, weight loss, GI bleeding, persistent vomiting) — endoscopy if indicated; serum magnesium if on diuretics or long-term PPI therapy
Short-term use (<8 weeks)	No routine monitoring required
Long-term use (>8–12 weeks)	Serum magnesium (especially if on diuretics, digoxin); vitamin B12 annually; reassess indication for continued PPI use
If on warfarin	INR monitoring when initiating or stopping PPI
If on digoxin	Digoxin levels, especially if hypomagnesaemia suspected
Zollinger-Ellison Syndrome	Gastric acid output measurements; serum gastrin levels periodically

Brands in India

Tablets (20 mg, 40 mg):

Pantocid™ (Sun Pharma)
Pan™ (Alkem)
Pantop™ (Aristo)
P-40™, Pantozee™
Nupenta™ (Zydus)
Pansec™
Protium™

Injection (40 mg):

Pantocid IV™ (Sun Pharma)
Pan IV™ (Alkem)
Pantop IV™ (Aristo)

Fixed-Dose Combinations (Examples):

Pantoprazole + Domperidone (e.g., Pantocid-D, Pan-D) — commonly used but monitor for QT prolongation with domperidone
Pantoprazole + Itopride (e.g., Pantocar-IT)
Pantoprazole + Levosulpiride

⚠️ Note on Domperidone FDCs: Monitor for QT prolongation risk, especially in elderly, cardiac patients, or those on other QT-prolonging drugs. Domperidone dose should not exceed 30 mg/day.

Price range (INR)

Formulation	Price Range	Notes
20 mg tablet	₹1.50–₹5.00 per tablet	NLEM listed
40 mg tablet	₹2.50–₹10.00 per tablet	NLEM listed
40 mg injection	₹35–₹100 per vial	—
FDCs (Pantoprazole + Domperidone)	₹4–₹12 per tablet	—

Regulatory: Listed under NLEM 2022 (40 mg tablet); NPPA price controlled for scheduled strengths

Clinical pearls

Preferred PPI with clopidogrel — Pantoprazole has minimal CYP2C19 inhibition compared to omeprazole and esomeprazole; preferred choice when PPI is required in patients on dual antiplatelet therapy post-ACS/PCI
Timing of administration is critical — Administer 30–60 minutes before the first meal of the day; PPIs require active acid secretion (stimulated by food) for optimal activation in parietal cells
De-escalation and deprescribing — Review indication periodically; many patients continue PPIs beyond appropriate duration; step-down to H2 blocker or on-demand PPI after healing; avoid indefinite therapy without clear indication
Rule out malignancy — Always consider endoscopy in patients with alarm features (dysphagia, weight loss, GI bleeding, persistent vomiting, anaemia) or non-responders to adequate PPI therapy; PPIs can mask symptoms of gastric cancer
Monitor long-term users — Check magnesium (especially if on diuretics), vitamin B12 annually, and assess bone health in those with osteoporosis risk factors; ensure adequate calcium and vitamin D intake
FDC caution — Pantoprazole + Domperidone combinations are widely prescribed in India; be aware of domperidone-associated QT prolongation risk, especially in elderly and cardiac patients

Version

RxIndia v1.0 — 28 Apr 2025

Reference

CDSCO Product Information
Indian Pharmacopoeia (IP)
National Formulary of India (NFI)
National List of Essential Medicines (NLEM) 2022
API Textbook of Medicine
AIIMS Drug Formulary and Treatment Protocols
ICMR Guidelines
Harrison's Principles of Internal Medicine
Goodman & Gilman's The Pharmacological Basis of Therapeutics
IAP Guidelines (paediatric dosing support)
WHO Essential Medicines List (paediatric support)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...